


Characteristic & Number (\%) of evaluations, N=209 & Count of unique studies, N=63\\
\hline
Type of comparison &  & \\
\hline
\hspace{1em}PCV7 vs NoVax & 24 (11\%) & 14\\
\hline
\hspace{1em}PCV10 vs NoVax & 77 (37\%) & 33\\
\hline
\hspace{1em}PCV13 vs NoVax & 64 (31\%) & 31\\
\hline
\hspace{1em}PCV13 vs PCV10 & 32 (15\%) & 23\\
\hline
\hspace{1em}Others & 12 (6\%) & 8\\
\hline
Number of doses &  & \\
\hline
\hspace{1em}Four & 74 (35\%) & 21\\
\hline
\hspace{1em}Three & 116 (56\%) & 41\\
\hline
\hspace{1em}One/two & 10 (5\%) & 4\\
\hline
\hspace{1em}Unknown & 9 (4\%) & 2\\
\hline
Study perspective &  & \\
\hline
\hspace{1em}Healthcare/payer & 114 (55\%) & 45\\
\hline
\hspace{1em}Societal & 95 (45\%) & 32\\
\hline
Income group &  & \\
\hline
\hspace{1em}Low & 18 (9\%) & 6\\
\hline
\hspace{1em}Lower-middle & 40 (19\%) & 17\\
\hline
\hspace{1em}Upper-middle & 151 (72\%) & 43\\
\hline
Included herd effects & 70 (33\%) & 29\\
\hline
Included serotype replacement & 38 (18\%) & 17\\
\hline
Pneumonia efficacy endpoint & 209 (100\%) & 63\\
\hline
IPD efficacy endpoint & 205 (98\%) & 61\\
\hline
Otitis media efficacy endpoint & 177 (85\%) & 54\\
\hline
Included budget impact analysis & 54 (26\%) & 14\\
\hline
Study decision &  & \\
\hline
\hspace{1em}Cost-saving & 24 (11\%) & 15\\
\hline
\hspace{1em}Cost-effective & 158 (76\%) & 50\\
\hline
\hspace{1em}Not cost-effective & 27 (13\%) & 14\\
\hline

